Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is prostate cancer?
The prostate is a walnut-sized gland that sits below the bladder and makes part of the fluid in semen. Prostate cancer begins when cells in the gland start to grow out of control. Many prostate cancers grow so slowly that they never cause harm, while others are more aggressive. Because of this, treatment is matched carefully to how risky your specific cancer looks. When caught early, prostate cancer is one of the most curable cancers there is.
The main types
Doctors group prostate cancer by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Adenocarcinoma | Over 95% of cases — cancer that starts in the gland cells that make prostate fluid. |
| Low-risk / favorable | Slow-growing cancer that may only need monitoring (active surveillance) rather than immediate treatment. |
| Intermediate-risk | A middle group where treatment is usually recommended, guided by the Gleason score and PSA. |
| High-risk / aggressive | Faster-growing cancer that often needs combined treatment such as radiation plus hormone therapy. |
Staging, in plain terms
Doctors describe prostate cancer with TNM (tumor, nodes, metastasis) plus your PSA blood level and Gleason score (how abnormal the cells look). Together these sort you into low-, intermediate-, or high-risk — which matters more for choosing treatment than the stage number alone.
| TNM + risk groups | What it generally means |
|---|---|
| Stage I | A small cancer found only inside the prostate, often by chance. Frequently low-risk and watched closely. |
| Stage II | Still confined to the prostate but more substantial; sorted into favorable or unfavorable by PSA and Gleason score. |
| Stage III | Locally advanced — has grown just outside the prostate or into the seminal vesicles, but not to distant organs. |
| Stage IV | Spread to lymph nodes or distant sites like bone. Very treatable and often controlled for many years. |
The standard of care
Prostate Cancer is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Active surveillance
For many low-risk cancers, the safest choice is careful monitoring with PSA tests, exams, and occasional biopsies — treating only if it changes.
Radiation therapy
Highly effective and non-surgical. Given as external beam (including SBRT) or as seeds/implants placed in the gland (brachytherapy).
Surgery (prostatectomy)
Removing the prostate, often robotically — another standard cure for localized disease.
Hormone therapy
Lowers testosterone, which prostate cancer feeds on. Added to radiation for intermediate- and high-risk disease.
How radiation treatment works
Radiation uses focused, high-energy x-rays to damage the DNA of cancer cells so they can no longer divide. Healthy cells repair this damage better than cancer cells, so carefully aimed, fractionated treatment clears the cancer while protecting the bladder and rectum nearby. Modern image guidance and techniques like a gel spacer between the prostate and rectum make treatment more precise and reduce side effects. Sessions are painless and take only minutes.
The main ways radiation is delivered for prostate cancer:
Stereotactic body radiation (SBRT)
Delivers a precise, high dose in just 5 sessions over about two weeks. NCCN now recognizes SBRT as a standard option across all risk groups, with 5-year cancer-control rates above 90%.
Moderate hypofractionation
External-beam radiation over about 4-5 weeks (fewer, slightly larger doses than the old 8-9 week course) — now a standard schedule with equal control.
Brachytherapy
Radioactive seeds or temporary implants placed directly in the prostate, delivering dose from the inside while sparing nearby tissue. Can be used alone or as a boost.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
SBRT as a standard option (NCCN): Five-session stereotactic radiation is now endorsed across all risk groups, with reported 5-year biochemical control of roughly 91-97% depending on risk — equal to longer courses but far more convenient.[1]
NCCN Guidelines; PACE-B and HYPO-RT-PC trials
HYPO-RT-PC (ultrahypofractionation): A phase III trial showed seven larger radiation sessions worked as well as a conventional 8-week course for intermediate-risk disease, supporting much shorter treatment.[2]
HYPO-RT-PC randomized trial · PMID 31227373 (opens in a new tab)
Moderate hypofractionation guidelines: AUA/ASTRO/ASCO guidelines confirm 4-5 week schedules as standard, sparing patients weeks of daily visits with no loss of effectiveness.[3]
AUA/ASTRO/ASCO hypofractionation guideline
Common questions
Do I have to treat it right away? Not always. Many low-risk prostate cancers are safely watched with active surveillance, and treated only if they show signs of growing. Your team will help you decide.
Will radiation make me incontinent or impotent? Modern, image-guided radiation is designed to protect the bladder, rectum, and nerves. Side effects vary, and many men keep normal urinary and sexual function — discuss your specific risks with your team.
How long is treatment? It ranges from just 5 sessions with SBRT to about 4-5 weeks with moderate hypofractionation, or a single brachytherapy procedure.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- NCCN Guidelines; PACE-B and HYPO-RT-PC trials (no indexed identifier — see your care team) ↩
- Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385-395. (opens in a new tab) PMID 31227373 ↩
- AUA/ASTRO/ASCO hypofractionation guideline (no indexed identifier — see your care team) ↩